Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05551104 · ClinicalTrials.gov registry record · Phase 3
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
A Phase 3 study of High Blood Pressure and Postpartum Complication, sponsored by Loma Linda University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT05551104: Recruiting Phase 3 study of High Blood Pressure and Postpartum Complication, sponsored by Loma Linda University.
NCT05551104 is a Phase 3 study of High Blood Pressure and Postpartum Complication that is actively recruiting participants, run by Loma Linda University. The registered enrollment target is 500 participants, roughly in line with the 483-participant average among 23 other High Blood Pressure trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05551104, a Phase 3 study of High Blood Pressure and Postpartum Complication, is actively recruiting participants, sponsored by Loma Linda University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.
Primary Outcome
Requiring antihypertensive medication in the postpartum period, readmission for high blood pressure
Conditions Studied
Interventions
- DRUG Oral Nifedipine
- DRUG Oral Labetalol
Study Locations (1)
California
- Loma Linda University Health - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What NCT05551104 shows while recruiting
NCT05551104 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 483-participant average among 23 other High Blood Pressure trials with a reported enrollment target.
The record links to 3 conditions, with High Blood Pressure appearing as the primary indexed condition, and to 2 interventions - of which Oral Nifedipine is the first listed.
NCT05551104 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05551104 about?
NCT05551104 is a clinical study titled "Safest Choice of Antihypertensive Regimen for Postpartum Hypertension". The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.
What is the current status of trial NCT05551104?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2023-05-08. Estimated completion is 2027-12.
What conditions does trial NCT05551104 study?
This clinical trial studies the following conditions: High Blood Pressure, Postpartum Complication, Maternal Hypertension.
What interventions are being tested in trial NCT05551104?
The interventions under investigation include: Oral Nifedipine (DRUG), Oral Labetalol (DRUG).
Who is sponsoring clinical trial NCT05551104?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05551104 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Blood Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05551104's enrollment target sits among peer trials
500 5th of 23 higher than 19 of 23 other High Blood Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)
RECRUITING · Phase 3
-
Addressing Hypertension Care in Africa Program
RECRUITING · NA
-
Blood Pressure Care for Advancing Real-World Evidence (BPCARE)
RECRUITING · NA
-
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
RECRUITING · NA
-
Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region Project 1 - Epidemiology (ACHIEVE P1-EPI)
RECRUITING · NA
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI